초록 ▼

An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric mater

An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of the particulate material will reduce the porosity of the polymer or otherwise obstruct the diffusion of the pharmaceutically active ingredient being released, thereby slowing its rate of release. In this way, it is possible to regulate the release rate and/or initial burst of the device, simply by adjusting the amount of particles/particulate material in the first layer, instead of having to adapt the size of the device to the desired release pattern, which requires expensive changes in production equipment and manufacturing processes.

대표청구항 ▼

1. An intrauterine device comprising at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between 10 and 60 v/v % of at least one particulate material is dispersed and/or incorporated in said first polymeric material,

1. An intrauterine device comprising at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between 10 and 60 v/v % of at least one particulate material is dispersed and/or incorporated in said first polymeric material, and wherein the particulate material is inert and has semi-spherical, ellipsoidal, or cylindrical shaped particles having a mean particle diameter of between 3.6 μm and 100 μm as measured by laser scattering using volumetric measurements based on an approximately spherical particle shape. 2. An intrauterine device according to claim 1, wherein the at least one particulate material is an inert inorganic or organic material. 3. An intrauterine device according to claim 1, wherein the at least one particulate material has a mean particle size of no greater than 50 μm; no greater than 30 μm, no greater than 20 μm, or 10 μm. 4. An intrauterine device according to claim 1, wherein the at least one particulate material is selected from the group comprising magnesium stearate, bentonite, talc, clay, calcium stearate, stearic acid, sodium stearyl fumarate and calcium sulphate. 5. An intrauterine device according to claim 1, wherein the at least one particulate material is talc. 6. An intrauterine device according to claim 1, where the at least one particulate material is surface-treated and/or modified to alter the three-dimensional shape or the hydrophilic/hydrophobic properties of the material. 7. An intrauterine device according to claim 1, wherein the thickness of the at least one first layer is between 0.05 mm and 3 mm, between 0.05 mm and 2 mm, between 0.1 mm and 2 mm or between 0.2 mm and 1 mm. 8. An intrauterine device according to claim 1, wherein an outer layer of the intrauterine device is the at least one first layer. 9. An intrauterine device according to claim 1, wherein the at least one pharmaceutically active ingredient is incorporated/dissolved in at least one second layer which may be made of at least one second polymeric material, and wherein said at least one first layer at least partly encapsulates said second layer. 10. An intrauterine device according to claim 9, wherein said at least one second layer is divided into sections, each of which comprises an individual active ingredient. 11. An intrauterine device according to claim 9, wherein said at least one first layer does not contain any pharmaceutically active ingredient(s). 12. An intrauterine device according to claim 9, which further comprises a central inert core that does not contain any active ingredient, and wherein said at least one second layer at least partly encapsulates the core, and said at least one first layer at least partly encapsulates said second layer. 13. An intrauterine device according to claim 9, wherein the at least first polymeric material of the first and/or second layer, and optionally the core, is at least one inert thermoset or thermoplastic elastomer. 14. An intrauterine device according to claim 12, wherein the core is made of a thermoplastic polymer, and the first and second polymeric material of the first and second layers respectively, are a thermoset elastomer or silicone. 15. An intrauterine device according to claim 13, wherein the thermoset elastomer is a pharmaceutically acceptable silicone or polydimethylsiloxane. 16. An intrauterine device according to claim 1, wherein the at least one active ingredient is at least one contraceptive agent, an estrogenic steroid, or a progestational steroid. 17. An intrauterine device according to claim 1, wherein the at least one active ingredient is at least one spermicide, an antimicrobial agent or an anti-viral agent. 18. An intrauterine device according to claim 1, which is a vaginal ring. 19. A method for reducing the rate of diffusion of an active ingredient though a polymeric material in an intrauterine device, wherein said method comprises incorporating at least one semi-spherical, ellipsoidal, or cylindrical shaped inert particulate material into said polymeric material, thus forming the intrauterine device of claim 1. 20. The method according to claim 19, wherein the particulate material has a mean particle size of between 3.6 μm-50 μm; between 5 μm-30 μm or between 10 μm-20 μm. 21. The method according to claim 19, wherein the at least one particulate material is selected from the group consisting of magnesium stearate, bentonite, talc, clay, calcium stearate, stearic acid and calcium sulphate. 22. A method of manufacturing an intravaginal ring according to claim 18, wherein the at least one first layer is prepared by injection moulding or by extrusion. 23. The method according to claim 22, wherein the at least one particulate material is selected from the group consisting of magnesium stearate, bentonite, talc, clay, calcium stearate, stearic acid and calcium sulphate. 24. The method according to claim 22, wherein the at least one semi-spherical, ellipsoidal, or cylindrical shaped inert particulate material is dispersed, dissolved and/or incorporated in the at least first polymeric material during the injection moulding or extrusion step. 25. The method according to claim 22, wherein the intravaginal ring further comprises at least one second layer and/or an inert core, and wherein said first layer and said second layer and/or said core is formed simultaneously or separately.